title: Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes.
abstract: The present prospective study seeks to evaluate overall and disease free survival, response and organ preservation rate, and toxicity of an intensive chemotherapy regimen (CT) followed by unconventional radiotherapy (RT) in patients with locally advanced operable head and neck cancer. Between January 1998 and December 2006 (June 2005), 115 patients with locally advanced, operable head and neck cancer were evaluated. A total of 333 cycles of neoadjuvant CT (cisplatin-5FU, days 1, 14, 28) followed by hyperfractionated/accelerated radiotherapy were given to 108 patients. A total of 108 patients were evaluable and received the planned CT-RT treatment. Two months after the end of RT, 97.2% of patients had a clinical complete remission of the primary and 67.5% of the neck node site. The overall survival was 55% and cause-specific survival was 73% at 5 years. Of the 33 relapsed patients, 12 recurred only at the primary site and 10 patients had distant metastases. The overall organ preservation rate was 73.5%. The chemotherapy regimen reported an overall cardiotoxicity from 5FU in 14% of patients, with severe toxicity in 3%. The radiotherapy schedule developed 84% of Grade 3-4 mucositis in the observed patients. The accelerated CT-RT regimen is able to achieve a high rate of larynx preservation, a good tolerability, and a satisfactory cause-specific overall survival.
authors.affiliation: Department of Radiation Therapy, Centro di Riferimento Oncologico, National Cancer Institute, Via Franco Gallini 2, 33081, Aviano, Italy. gfranchin@cro.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Franchin
authors.forename: Emanuela
authors.initials: E
authors.lastname: Vaccher
authors.forename: Doriano
authors.initials: D
authors.lastname: Politi
authors.forename: Emilio
authors.initials: E
authors.lastname: Minatel
authors.forename: Carlo
authors.initials: C
authors.lastname: Gobitti
authors.forename: Renato
authors.initials: R
authors.lastname: Talamini
authors.forename: Simon
authors.initials: S
authors.lastname: Spazzapan
authors.forename: Maria Gabriella
authors.initials: MG
authors.lastname: Savignano
authors.forename: Mauro G
authors.initials: MG
authors.lastname: Trovò
authors.forename: Luigi
authors.initials: L
authors.lastname: Barzan
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016879:Salvage Therapy
references.citation: Radiother Oncol. 2007 Jul;84(1):5-10
references.pmid: 17493700
references.citation: N Engl J Med. 1998 Jun 18;338(25):1798-804
references.pmid: 9632446
references.citation: J Clin Oncol. 2003 Jan 15;21(2):320-6
references.pmid: 12525525
references.citation: J Clin Oncol. 2004 May 1;22(9):1743-52
references.pmid: 15117998
references.citation: Radiother Oncol. 2003 Mar;66(3):271-6
references.pmid: 12742266
references.citation: N Engl J Med. 1991 Jun 13;324(24):1685-90
references.pmid: 2034244
references.citation: Laryngoscope. 1988 Nov;98(11):1205-11
references.pmid: 3054373
references.citation: J Clin Oncol. 2004 Sep 1;22(17):3540-8
references.pmid: 15337803
references.citation: J Clin Oncol. 2006 Mar 1;24(7):1064-71
references.pmid: 16505425
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1405-10
references.pmid: 11870186
references.citation: Cancer. 1990 Apr 15;65(8):1685-91
references.pmid: 2317751
references.citation: Am J Clin Oncol. 2005 Aug;28(4):371-8
references.pmid: 16062079
references.citation: Int J Radiat Oncol Biol Phys. 1992;23(4):705-13
references.pmid: 1618662
references.citation: J Clin Oncol. 2006 Feb 1;24(4):593-8
references.pmid: 16380415
references.citation: J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6
references.pmid: 10601378
references.citation: N Engl J Med. 2007 Oct 25;357(17):1705-15
references.pmid: 17960013
references.citation: J Clin Oncol. 2002 Oct 1;20(19):3964-71
references.pmid: 12351593
references.citation: Oral Oncol. 2005 May;41(5):526-33
references.pmid: 15878759
references.citation: N Engl J Med. 2003 Nov 27;349(22):2091-8
references.pmid: 14645636
references.citation: J Clin Oncol. 2005 May 1;23(13):3008-15
references.pmid: 15860857
references.citation: J Clin Oncol. 2004 Jan 1;22(1):69-76
references.pmid: 14657228
references.citation: J Natl Cancer Inst. 1994 Feb 16;86(4):265-72
references.pmid: 8158680
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3061-9
references.pmid: 15284256
references.citation: J Natl Cancer Inst. 1996 Jul 3;88(13):890-9
references.pmid: 8656441
references.citation: Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16
references.pmid: 10924966
references.citation: J Natl Cancer Inst. 1996 May 1;88(9):583-9
references.pmid: 8609658
references.citation: Cancer J. 2002 Jul-Aug;8(4):311-21
references.pmid: 12184409
references.citation: Lancet. 2000 Mar 18;355(9208):949-55
references.pmid: 10768432
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544